Comparison of Spinal Anesthesia Adjuvant and Quadratus Lumborum Block on the Opioid Requirement and Perioperative Pain of Laparoscopic Kidney Transplant Donor
Launched by INDONESIA UNIVERSITY · Jan 2, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of pain management for patients undergoing laparoscopic kidney transplant donation. The researchers want to see if using spinal anesthesia with an additional medication or a specific nerve block (called the quadratus lumborum block) will reduce the need for opioids and lower pain levels during and after surgery. This is important because effective pain management can help patients recover more comfortably.
To participate in this study, you need to be between 18 and 65 years old, have a body mass index (BMI) of 35 or less, and be in generally good health (specifically, you should be classified as ASA physical status 1 or 2, which means you are healthy or have mild health issues). If you join, you can expect to receive one of the two pain management techniques during your surgery. However, people with certain health conditions, such as serious heart problems or infections near the spine, cannot participate. This trial is currently recruiting participants, so if you or someone you know meets the eligibility criteria, it could be a good opportunity to contribute to important research in pain management.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18-65 years undergoing laparoscopic donor nephrectomy
- • Patients with BMI ≤ 35 kg/m2
- • Patients with American Society of Anesthesiology (ASA) physical status 1-2
- • Patients who are willing to participate in this study
- Exclusion Criteria:
- • Cardiovascular disease (uncontrolled stage 2 hypertension, heart failure, arrhytmia)
- • Recent onset cerebrovascular diseasae of \< 3 months
- • Infection on spinal site
- • Coagulopathy
- • Elevated intracranial pressure
- • Severe renal or liver dysfunction
- • Valvular heart disease or atrioventricular block
About Indonesia University
Indonesia University is a leading academic institution dedicated to advancing healthcare through rigorous clinical research. As a trial sponsor, the university leverages its extensive expertise in medical science and collaboration with top-tier researchers to design and implement innovative clinical trials. Committed to ethical standards and patient safety, Indonesia University aims to contribute to the global body of knowledge in medicine, enhance therapeutic options, and improve health outcomes for diverse populations. Through its comprehensive approach, the university fosters an environment of scientific inquiry and collaboration, driving progress in clinical research and education.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jakarta Pusat, Jakarta, Indonesia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported